Recent basic and translational research has highlighted the promise of tissue‐specific stem cells from the skeleton or skeletal stem cells (SSCs). While they have been shown to contribute to skeletal development and regeneration, we still lack a full understanding of how these cells react during inflammatory bone disease.
Clinical trials employing cultured human bone marrow mesenchymal stem cells (hBM‐MSCs) have demonstrated the presence of significant inter‐donor variability in biological functions and clinical efficacy.
Osteoarthritis (OA) patients suffer from irreversible and challenging to repair defects in the cartilage; however, mesenchymal stem cell (MSC)-based cartilage regeneration may represent an exciting approach if we can inhibit the excessive chondrocyte hypertrophy observed in the inflammatory intra‐articular conditions of OA.
While attaining a critical number of in vitro expanded progenitor cells provides the key driving force in a cell‐based regenerative construct, the standard expansion protocols currently employed affect the initial cellular phenotype due to a focus on rapid expansion and not maintenance of progenitor potential.
The Stem Cells Portal is a shared platform for the STEM CELLS and STEM CELLS Translational Medicine sister journals, providing up-to-the-minute coverage of the latest research from bench science and developments to clinical applications.